Rechter.

Vectorious

Strategic investment

What happens to the heart between clinic visits? In heart failure, rising pressure can signal trouble before symptoms do. A miniature implant makes those changes visible—connecting daily life with physician-guided care.

I worked with the team to give Vectorious’s evolving plans a coherent, tangible form at each stage of the strategic-investment process.

Vectorious, acquired by Edwards Lifesciences in 2025, develops V-LAP, an investigational platform that measures pressure inside the heart to support heart-failure care.

vectoriousmedtech.com
A woman uses a smartphone with a chest-worn monitoring device, alongside a clinician reviewing patient information.
Patient monitoring dashboard with pressure trends, a waveform chart, and a highlighted status indicator.
Comparison of the V-LAP system and existing implantable sensors across patient use, physician oversight, and scalability.
Comparison of seated measurements using an external unit with a proposed autonomous implant taking readings during travel, sleep, exercise, and swimming.
Four sequences of project materials tracing the first meeting, technical leadership discussions, five-year roadmap, and website.